Skip to main content
OpenTrials
Completed

NCT Number: NCT01752322

Efficacy and Tolerability of Lidocaine Plaster for Treatment of Long-term Local Nerve Pain

The purpose of this trial is to investigate the efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain in comparison to placebo plaster.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

AUT004, Klagenfurt, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects aged 18 years or older.
  • Subjects suffering from moderate to severe localized chronic PoNP (post operative neuropathic pain) pain following surgery (e.g., thoracotomy, total/partial knee replacement, cholecystectomy, mastectomy, inguinal hernia repair, varicose vein stripping).
  • Localized PoNP present for at least 3 months.
  • Size of the affected painful skin area is not larger than the size of 3 plasters.
  • Intact skin besides the scar of surgery in the area of plasters application
  • Baseline average pain intensity of 4 or greater on the 11 point pain intensity Numeric Rating Scale.

Exclusion criteria

  • Participation in another trial (with medicine or a device under investigation) in parallel or less than 30 days prior to enrollment in this trial.
  • Previous enrollment in this trial.
  • History of dependency or active drug abuse (alcohol, medication) during the 1 year prior to enrollment.
  • Evidence or history (during the 3 years prior to enrollment) of neurotic personality or psychiatric illness that in the investigator's opinion may affect efficacy or safety assessments or may compromise the subjects safety during trial participation.
  • Pregnant or breastfeeding women or women of childbearing potential who are sexually active without satisfactory contraception.
  • Any surgery performed in the 3 months prior to enrollment, which may affect efficacy or safety assessment.
  • Any surgery scheduled or expected during the trial.
  • Clinically significant disease (e.g., acquired immunodeficiency syndrome) or condition that may affect efficacy or safety assessments, or any other reason which, in investigator's opinion, may preclude the subject's participation in the trial.
  • History of malignancy (with the exception of neoplasia related to the trial indication) within 2 years prior to enrollment.
  • Subject with PoNP related to a surgery due to neoplasia: suspected residual neoplasia or metastases.
  • Pending litigation due to chronic pain or disability.
  • Total anesthesia in the cutaneous area neurologically related to the location of the surgical intervention.
  • Hypersensitivity to the lidocaine 5% medicated plaster, its excipients, or anesthetics of the amide type.
  • Any former use of topical lidocaine in the area of localized chronic PoNP.
  • Severe renal, hepatic or heart disorder.

Treatment and study plan

Lidocaine 5% medicated plaster

Drug

Placebo plaster

Drug

Primary outcomes

  1. Change from baseline of recorded average pain intensity values during the last 24 hours, averaged over the 7 days of Week 12 of the Double-blind Treatment Period.

    Time frame: Days 78-85

Secondary outcomes

  1. Mean pain intensity based on the average pain intensity during the last 24 hours, calculated over the last 4 weeks and 12 weeks of the Double blind Treatment Period.

    Time frame: up to 12 weeks

  2. Mean pain intensity based on the current pain intensity before plaster removal, calculated over the last 7 days, 4 weeks, and 12 weeks of the Double blind Treatment Period.

    Time frame: up to 12 weeks

  3. Weekly mean pain intensity before plaster removal based on the average pain intensity during the last 24 hours.

    Time frame: up to 12 weeks

  4. Weekly mean pain intensity before plaster removal based on current pain intensity before plaster removal.

    Time frame: up to 12 weeks

  5. Final score of the painDETECT Pain Questionnaire during the Double blind Treatment Period.

    Time frame: Day 85

  6. Pain intensity from mechanical dynamic allodynia (brush) testing.

    Time frame: Day 85

  7. Anxiety and depression scores of HADS.

    Time frame: Day 85

  8. The weighted Health Status Index of quality of life by means of EQ 5D.

    Time frame: Day 85

  9. Total score in quality of sleep using CPSI.

    Time frame: Day 85

  10. Mean pain intensity change from baseline based on the average pain intensity during the last 24 hours, calculated over the last 4 weeks and 12 weeks of the Double blind Treatment Period.

    Time frame: up to 12 weeks

  11. Mean pain intensity change from baseline based on the current pain intensity before plaster removal, calculated over the last 7 days, 4 weeks, and 12 weeks of the Double blind Treatment Period.

    Time frame: up to 12 weeks

  12. Weekly mean pain intensity change from baseline before plaster removal based on the average pain intensity during the last 24 hours.

    Time frame: up to 12 weeks

  13. Weekly mean pain intensity change from baseline before plaster removal based on current pain intensity before plaster removal.

    Time frame: up to 12 weeks

  14. Change from baseline in the total score of the painDETECT Pain Questionnaire during the Double blind Treatment Period.

    Time frame: Day 85

  15. Change from baseline in pain intensity from mechanical dynamic allodynia (brush) testing.

    Time frame: Day 85

  16. Change from baseline in anxiety and depression scores of HADS.

    Time frame: Day 85

  17. Change from baseline in total score of quality of life by means of EQ 5D.

    Time frame: Day 85

  18. Change from baseline in total score in quality of sleep using CPSI.

    Time frame: Day 85

Sponsors and collaborators

Lead sponsor

Grünenthal GmbH

Industry

Registry information

Official study title

Efficacy and Safety of Lidocaine 5% Medicated Plaster in Localized Chronic Post-operative Neuropathic Pain

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Dec 19, 2012
Registry last updated
Jul 6, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.